This article first appeared on GuruFocus.

Harmony Biosciences Holdings Inc (NASDAQ:HRMY) is set to release its Q3 2025 earnings on Nov 4, 2025. The consensus estimate for Q3 2025 revenue is $223.68 million, and the earnings are expected to come in at $0.77 per share. The full year 2025's revenue is expected to be $845.65 million, and the earnings are expected to be $3.18 per share. More detailed estimate data can be found on the Forecast page.

Warning! GuruFocus has detected 3 Warning Sign with FLYW.

Is HRMY fairly valued? Test your thesis with our free DCF calculator.

Revenue estimates for Harmony Biosciences Holdings Inc (NASDAQ:HRMY) have increased from $844.14 million to $845.65 million for the full year 2025. However, estimates have declined from $990.60 million to $980.85 million for 2026 over the past 90 days. Earnings estimates have increased from $3.13 per share to $3.18 per share for the full year 2025, while they remain flat at $3.99 per share for 2026 over the past 90 days.

In the previous quarter ending on 2025-06-30, Harmony Biosciences Holdings Inc's (NASDAQ:HRMY) actual revenue was $200.49 million, which missed analysts' revenue expectations of $203.60 million by -1.53%. Harmony Biosciences Holdings Inc's (NASDAQ:HRMY) actual earnings were $0.68 per share, which missed analysts' earnings expectations of $0.70 per share by -2.72%. After releasing the results, Harmony Biosciences Holdings Inc (NASDAQ:HRMY) was down by -1.69% in one day.

Based on the one-year price targets offered by 11 analysts, the average target price for Harmony Biosciences Holdings Inc (NASDAQ:HRMY) is $44.00, with a high estimate of $62.00 and a low estimate of $31.00. The average target implies an upside of 54.01% from the current price of $28.57.

Based on GuruFocus estimates, the estimated GF Value for Harmony Biosciences Holdings Inc (NASDAQ:HRMY) in one year is $55.48, suggesting an upside of 94.19% from the current price of $28.57.

Based on the consensus recommendation from 11 brokerage firms, Harmony Biosciences Holdings Inc's (NASDAQ:HRMY) average brokerage recommendation is currently 2.2, indicating an \\"Outperform\\" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.